IL1R2 _ CD121b Protein
- Known as:
- IL1R2 _ CD121b Protein
- Catalog number:
- 10111-H02H
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- IL1R2 _ CD121b Protein
Related genes to: IL1R2 _ CD121b Protein
- Gene:
- IL1R2 NIH gene
- Name:
- interleukin 1 receptor type 2
- Previous symbol:
- IL1RB
- Synonyms:
- CD121b
- Chromosome:
- 2q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-30
- Date modifiied:
- 2016-10-05
Related products to: IL1R2 _ CD121b Protein
Related articles to: IL1R2 _ CD121b Protein
- This study utilized a multi-omics and computational biology framework to investigate the therapeutic potential of the Traditional Chinese Medicine (TCM) formula Buti Huatan Tang (BTHTT) against chronic obstructive pulmonary disease (COPD). Significant physiological improvements were observed in a rat model following BTHTT intervention. Histological analysis showed a reversal of lung pathological damage, while biochemical assays, and transcriptomics confirmed the normalization of IL-1β and IL-1R2 levels. Additionally, metabolic profiling revealed that BTHTT corrected disruptions in T3 and T4 thyroid hormone levels. A negative correlation was observed between the IL-1β/IL-1R2 axis and these thyroid hormones, indicating that their regulation is associated with the formula's therapeutic effect. Beyond direct measurements, machine learning algorithms identified ten COPD signature genes from clinical databases. Pathway enrichment analysis suggests that BTHTT may act through cytokine-cytokine-receptor interactions and thyroid hormone synthesis pathways. Furthermore, while 283 components were identified in vivo, compounds such as tanshinone IIA and cryptotanshinone are currently considered candidate active substances. Their role as primary drivers is supported by a model in which they stably bind to IL-1R2; this inference is based on molecular docking and molecular dynamics (MD) simulations rather than direct experimental isolation. Overall, the data support a model in which BTHTT exerts a multi-target effect on COPD by modulating inflammation and metabolic homeostasis. This integrated approach provides a refined scientific basis for the clinical application of BTHTT and highlights specific pathways for future experimental validation. - Source: PubMed
Publication date: 2026/03/13
Zha XinGong Wen-WeiLi Xue-YingXia QingRuan Jing-HuaTan RongZhu Zhu-ShengLiu Shao-Bo - The lack of reliable diagnostic tools and relapse monitoring for latent tuberculosis infection (LTBI) constitutes a major obstacle to global tuberculosis (TB) control. This highlights an urgent need for robust animal models and predictive biomarkers. To address this, we report the successful establishment of a rapid murine model of recapitulating the active, latent, and relapse phases of TB within a compressed ten-week timeframe-hence termed the rapid multi-stage TB murine model. In this model, mice were first intravenously infected with , followed by a four-week isoniazid (INH) regimen starting at two weeks post-infection. By week six, pulmonary bacterial loads in most mice dropped below the detection limit, signifying the establishment of latency. Reactivation was subsequently triggered by a four-week administration of anti-TNF-α (Tumor Necrosis Factor-α) monoclonal antibody. Leveraging this reproducible and time-efficient model, we performed transcriptomic profiling of peripheral blood and identified a distinct sixteen-gene signature (including , , , , , , , , , , , , , , , ) that dynamically tracks disease progression. Collectively, these findings not only provide a valuable and efficient preclinical tool but also deliver transformable candidate biomarkers with immediate potential to guide the development of novel diagnostic strategies for LTBI surveillance and management. - Source: PubMed
Publication date: 2026/03/11
Li HaifengWang JunfeiWang YuLiu FanTang JunSun MengmengZhan Lingjun - Asthma is a chronic inflammatory respiratory disease characterized by significant heterogeneity, which complicates accurate patient classification and management. With the aim of defining new, reliable biomarkers, we previously evaluated the potential of 94 genes to differentiate allergic asthma (AA) from nonallergic asthma (NA) based on their expression in peripheral blood mononuclear cells (PBMCs). Here, the most promising biomarkers were further analyzed in a 2-year longitudinal cohort of 24 healthy controls (HCs), 18 NA patients, and 51 AA patients. - Source: PubMed
Publication date: 2026/03/26
Cremades-Jimeno LucíaLópez-Ramos MaríaBaos SelenFernández-Santamaría Rubénde Pedro María AMahíllo-Fernández IgnacioRosales-Ariza CristinaOlaguibel José MDel Pozo VictoriaCaballero María LLuna-Porta Juan AQuirce SantiagoBarroso BlancaBetancor DianaValverde-Monge MarcelaSastre JoaquínCárdaba Blanca - Poly(ADP-ribose) polymerase (PARP) inhibition (PARPi) is a precision medicine strategy in advanced prostate cancer, with the greatest benefit seen in a subset of patients with homologous recombination repair (HRR) gene alterations. Combination approaches may expand activity beyond HRR-altered disease. We conducted a phase 2 study of the PARP inhibitor olaparib in combination with the anti-PD-L1 antibody durvalumab in an HRR-unselected population of men with metastatic castration-resistant prostate cancer (mCRPC). - Source: PubMed
Publication date: 2026/03/25
Li ChennanMadan Ravi ALee Min-JungLee SunminSato NahokoRastogi ShraddhaShrestha RoshanAragon-Ching Jeanny BGoswami MeghaliDonahue Renee NCordes Lisa MBaj AnnaSeo Clara C YTerrigino Nicholas TBright John RHennigan S ThomasKing Isaiah MTrostel Shana YFenimore John MLiu YiCalzone Kathleen ASchlom JeffreyGulley James LDahut William LFigg William DSowalsky Adam GLee Jung-MinKarzai Fatima - Ischemic stroke is a leading cause of death and long-term disability worldwide. Recanalization therapies, including thrombolysis and mechanical thrombectomy, restore blood flow, yet many patients experience poor outcomes, a phenomenon known as futile recanalization. Given the short therapeutic window for ischemic stroke, identifying early biomarkers to guide targeted interventions and improve outcomes is critical. - Source: PubMed
Publication date: 2026/03/25
Bui Truong AnMa YonglieJickling Glen CWinship Ian R